On January 24, 2020 Oncopeptides AB (Nasdaq Stockholm: ONCO) reported that it will host a webcast at 11am (CET) on Monday, January 27th 2020 where CEO Jakob Lindberg will present and explain melflufen’s mechanism of action (Press release, Oncopeptides, JAN 24, 2020, View Source [SID1234553532]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference call for investors, analysts and the media, Monday, January 27th 2020, at 11 (CET).
The conference call will also be streamed on the corporate website www.oncopeptides.com and via the link below.
The presentation will be available at:
www.oncopeptides.com / Investor Relations / Presentations / Presentation webcast melflufen mechanism-of-action/
For more information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: [email protected]
Cell phone: +46 70 853 72 92
This information was submitted for publication at 18.30 CET January 24, 2020.
About melflufen
Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.